MarketMoodz
AbbVie Scores Dermatology Wins, Buys Apogee for $10.9B
AbbVie reported dual regulatory moves: the FDA has approved SKYRIZI for pediatric plaque psoriasis and the EMA’s CHMP issued a positive opinion recommending RINVOQ for vitiligo and severe alopecia areata in Europe, while the company is set to acquire Apogee Therapeutics for $10.9 billion. These developments expand AbbVie’s addressable dermatology market and add pipeline optionality ahead of its July 31 earnings print.
Key Takeaways
- FDA approval extends SKYRIZI (risankizumab) to pediatric patients, with a new 55 mg pre-filled syringe to support weight‑based dosing under 40 kg; 150 mg PFS and pen remain for patients ≥40 kg.
- CHMP adopted a positive opinion recommending RINVOQ (upadacitinib) for adult and adolescent non‑segmental vitiligo and for severe alopecia areata at 15 mg and 30 mg doses.
- AbbVie will acquire Apogee Therapeutics for $10.9 billion, adding immunology pipeline assets that could bolster long‑term growth but may dilute near‑term earnings.
- Analyst consensus is generally constructive: mean price target ~$257.09 with firms like Piper Sandler at $298 and Canaccord at $273.
- Upcoming Q2 2026 earnings on July 31 (consensus EPS $3.77, revenue $16.77B) and regulatory/payer timelines are the next catalysts to price in these wins.
People Involved
- No specific individuals mentioned
Entities Involved
- AbbVie (ABBV)Biopharma company; maker of SKYRIZI and RINVOQ; acquirer of Apogee Therapeutics
- Apogee TherapeuticsBiotech being acquired by AbbVie for $10.9 billion
- U.S. Food and Drug Administration (FDA)Regulatory body that reportedly approved pediatric SKYRIZI indication
- European Medicines Agency - CHMPCommittee that adopted a positive opinion for RINVOQ in vitiligo and alopecia areata
- Johnson & Johnson (J&J)Competitor in dermatology (e.g., Stelara)
- Merck (MRK)Competitor in immunology/dermatology
- Bristol Myers Squibb (BMY)Competitor in immunology/dermatology
MarketMoodz Analysis
For investors, these regulatory actions and the Apogee deal reinforce AbbVie’s strategy to lean into dermatology as a growth engine. Pediatric approval and a 55 mg pre-filled syringe that facilitates weight‑based dosing under 40 kg expand SKYRIZI’s addressable market and simplify prescribing—both of which can accelerate adoption and revenue upside if payers provide coverage. The CHMP positive opinion for RINVOQ would open a European growth channel in vitiligo and severe alopecia areata, categories with limited effective oral options and solid unmet need, which supports incremental top‑line contribution if full approvals follow.
The Apogee acquisition adds R&D optionality but introduces near‑term dilution and integration risk that investors must price in across the next 12–18 months. Historically, AbbVie has shown it can scale dermatology assets (SKYRIZI has been a key growth driver against competitors like J&J’s Stelara), but competitive dynamics, pricing pressure, and payer negotiations will determine how much of the incremental patient population converts to paid prescriptions. Watch for confirming primary sources (FDA label/press release, EMA documents, AbbVie SEC filings) and the July 31 earnings print for management’s revenue and margin assumptions, updated guidance, and comments on integration plans and expected synergies.
Source: Original Article